Dr. Negar Ashouri, Pediatric Infectious Disease

Dr. Negar Ashouri, Pediatric Infectious Disease

  • Negar Ashouri MD
  • Appointments:
    888-770-2462
  • Office: 714-509-8403
  • Specialties: Infectious Disease, Pediatrics
  • Board Certified: Pediatric Infectious Disease
  • Additional Languages: Farsi, Spanish

Dr. Negar Ashouri is board certified in pediatrics and pediatric infectious diseases. She completed medical school At St. George’s University School of Medicine in Grenada, West Indies. Dr. Ashouri completed her residency training at CHOC Hospital in Orange, followed by a year as Chief Resident. After serving her fellowship in pediatric infectious diseases at Children’s Hospital of Los Angeles, she returned to CHOC where she is currently a pediatric infectious disease specialist with clinical interests in Kawasaki disease and neonatal infections.

Clinical Interests

Kawasaki disease and neonatal infections

Research Focus

Bloodstream infections and drug trials

Negar Ashouri MD is on staff at CHOC Hospital in Orange and CHOC Mission Hospital.

Locations

CHOC Clinic
1201 W. La Veta Ave. Building: CHOC Clinic
Orange, CA 92868
phone: 888-770-2462
fax: 855-246-2329

CHOC at Mission Hospital
27700 Medical Center Rd Building #2 Suite 138
Mission Viejo, CA 9269

Western Medical Center
1001 N Tustin Ave
Santa Ana, CA 92705

Education

  • Medical School
    St George’s University School of Medicine, Grenada, West Indies
  • Pediatric Infectious Diseases Fellowship
    Children’s Hospital of Los Angeles, CA
  • Pediatrics Residency
    CHOC Hospital, Orange, CA

Academic Appointments

  • Assistant Clinical Professor
    University of California, Irvine, School of Medicine

Administrative Appointments

  • Infectious Disease, CHOC Specialists

Honors and Awards

  • Physician of Excellence
    OCMA, Multiple years

Lectures and Presentations

Bacteremic Urinary Tract Infection Compared to Primary Bacteremia in Children < 3 months. Is Pyelonephritis a Serious Bacterial Infection?”

Clinical and Laboratory Features of Pertussis During a California Epidemic.

Clinical and Microbiological Factors Affecting Outcome in Hospitalized Children with Candidemia.

Identification of Factors Affecting Incidence and Outcome of Candidemia in a Neonatal Intensive Care Unit for Developing Prophylaxis Strategies.

Impact of intra-abdominal pathology in late onset blood stream infections in neonatal intensive care patients.

Increasing ESBL Infections in Children- an Emerging Pediatric Challenge?

Micafungin Safety in Pediatric Patients in Clinical Practice

Outcome of late onset neonatal sepsis due to bacteremic urinary tract infections.

Overlaping seasonality of paraneumonic empyema and bacteremia due to Pneumococcus in Southern California Children, does influenza matter?

Predictors of Influenza Disease Severity and Resolution in Infants: Results of a National Collaborative Trial.

Safety of Micafungin in Infants less than 90 days of age

Six months versus six weeks of oral valganciclovir for infants with symptomatic congenital cytomegalovarius (CMV) disease with and without central nervous system involvement: Results of a randomized, double-blind, placebo-controlled, multinational study

Staphylococcus aureus (S aureus) Bacteremia in Hospitalized Infants Less Than Three Months of Age.

Streptococcus Pneumoiae Blood Stream Infections (BSI) in Hospitalized Children after Broad Utilizacion of Heptavalente Pneumococcal Conjugate Vaccine (PCV-7).

Two-Step Process for Clostridium difficile Testing in Pediatric Hematology/Oncology Patients – How Changes in the Lab Effect Patient Care.

Publications

Arrieta AC, Shea K, Dhar V, Cleary JP, Kukreja S, Morris M, Vargas-Shiraishi OM, Ashouri N, Singh J. Once-weekly liposomal amphotericin B as Candida prophylaxis in very low birth weight premature infants: a prospective, randomized, open-label, placebo-controlled pilot study. Clin Ther. 2010 Feb;32(2):265-71.

Chuang M, Singh J, Ashouri N, Katz M, Arrieta A. Listeria Meningitis after Influximab Therapy for Ulcerative Colitis. J Pediatr Gastroenterol Nutr. 2010 Mar;50(3):337-9.

Ashouri N, Takahashi M, Dorey F, and Mason W. Risk Factors for Non-Response to Therapy in Kawasaki Disease. J Pediatr. 2008 Sep;153(3):365-8.

Bennetto-Hood C, Aldrovandi GM, King JR, Woodman K, Ashouri N, and Acosta EP. Persistence of Nevirapine in Breastmilk After Discontinuation of Treatment. CID, 2007:45; 391-394.

Ashouri N, Singh J, Arrieta A. Micafungin in Pediatrics: when one size does not fit all. Expert Opin. on Drug Metab. & Toxicol. 2008 April; 4 (4): 463-469

Ashouri N, Mason W. MRSA in Los Angeles, an info sheet for Clinicians. Pediatric News, Vol 47, No.7, Summer 2006.

Amebic Encephalitis Caused by Balamuthia madrillaris: Report of Four Cases. Bakardjiev A. Azimi P, Ashouri N et al. Pediatric Infectious Disease Journal: 2003;22:447-452

Urinary Tract Infections in Neonates: How Aggressive a Workup and Therapy Ashouri N. Butler J et al Infections in Medicine 2003:20:98-102

The Effects of Triamcinalone on the Functional Recovery of the Rat Sciatic Nerve, Ashouri N. UCI’S Journal of Undergraduate Research

Presentations

Arrieta AC, Vargas-Shiraishi O, Ashouri N, Adler F, Singh J. Streptococcus Pneumoiae Blood Stream Infections (BSI) in Hospitalized Children after Broad Utilizacion of Heptavalente Pneumococcal Conjugate Vaccine (PCV-7). Accepted for poster presentation for the 2009 European Society for Paediatric Infectious Diseases (ESPID), Brussels, Belgium, June 09-13, 2009.

Ashouri N, Singh J, Vargas-Shiraishi O, Arrieta A. Clinical and Microbiological Factors Affecting Outcome in Hospitalized Children with Candidemia. Accepted for poster presentation for the 27th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID), Brussels, Belgium, June 09-13, 2009

Ashouri N, Singh J, Vargas-Shiraishi O, Arrieta A. Identification of Factors Affecting Incidence and Outcome of Candidemia in a Neonatal Intensive Care Unit for Developing Prophylaxis Strategies. Accepted for poster presentation for the 27th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID), Brussels, Belgium, June 09-13, 2009

Arrieta AC, Shea K, Dhar V, Cleary J, Kukreja S, Morris M, Ashouri N, Singh J: Safety and Efficacy of Liposomal Amphotericin B (L-AmB) as a Prophylactic Regimen for the Prevention of Candida Colonization and Systemic Infection in Very Low Birth Weight (VLBW) Premature Infants. Poster presentation at PAS, Honolulu, HI, May 2008.

Arrieta AC, Shea K, Dhar V, Cleary J, Kukreja S, Ashouri N, Singh J: Safety of Liposomal Amphotericin as a Once Weekly Antifungal Prophylactic Regimen in Very Low Birth Weight Premature Infants. Poster Presentation at ECCMID, Barcelona, Spain, April 2008.

Ashouri N, Takahashi M, Mason W. Variation and Risk Factor for Non-response to Treatment in Kawasaki Disease. IX International Kawasaki Disease Symposium. April 10-12, 2008. Taipei, Taiwan.

Singh J, Bendig EA, Vargas-Shiraishi OM, Wronski, SA, Ashouri N, Arrieta, AC Microbiology (Micro) of Community Acquired (CA) Blood Stream Infection (BSI) After Introduction of Streptococcus pneumoniae (SP) Conjugated vaccine and its impact on the reliability of traditional diagnostic criteria. Poster Presentation. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). September 2007. Chicago IL

Ashouri N, Mason W, Apparent Increase in Kawasaki Disease (KD) Cases Refractory to Intravenous Immunoglobulin 2007 Pediatric Academic Societies Meeting, May 5-8, Toronto, Canada.

Ashouri N, Ross L, Mason W. Voriconazole Use at CHLA. 43rd Annual IDSA, October 6-9 2005. San Francisco, California.

Arrieta AC, Shea K, Dhar V, Cleary J, Kukreja S, Morris M, Ashouri N, Singh J Safety and Efficacy of Liposomal Amphotericin B (L-AmB) as a Prophylactic Regimen for the Prevention of Candida Colonization and Systemic Infection in Very Low Birth Weight (VLBW) Premature Infants. Poster Presentation. Pediatric Academic Societies and Asian Society for Pediatric Research 2008 Joint Meeting. May 2008. Honolulu, Hawaii

Ashouri N, Vargas-Shiraishi O, Singh J, Arrieta A. Treatment (tx) of Pediatric Acute Hematogenous Skeletal Infections (ASHI): How aggressive should we be Poster presentation. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). September 14-17, 2003 Chicago Illinois

Ashouri N, Butler J, Vargas-Shiraishi OM, Singh J, and Arrieta AC. New Approach to the Management of Urinary Tract Infection in Neonates. A Challenge to Current Dogmas. Poster Presentation. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco California, September 1999. Accepted for publication Infections in Medicine.

Ashouri, N. The Effects of Triamcinalone on the Functional Recovery of the Rat Sciatic Nerve

9th Annual Excellence in Research Symposium, UCI

Kimberlin D, Ashouri N, Acosta E, Prichard M. Oseltamivir Pharmacokinetics, Dosing, and Resistance in Children

Our infectious disease specialists commonly treat:

  • Infectious diseases, including those caused by multi-resistant bacteria
  • Congenital and perinatal infections, including HIV
  • Opportunistic infections in the immunocompromised patient
  • Immunocompromised host
  • Respiratory infections
  • Viral and fungal infections
  • Recurrent fever or fever of unknown origin
  • Hepatitis A, B, C delta, E and G, as well as non-A – G
  • Tuberculosis and Lyme disease
  • Coccidiomycosis and other endemic fungal infections
  • Travel medicine for children

Health Topics

Medical staff giving a young girl a vaccination shot
Kids and the Immune System

Our immune system is a series of cells, tissues and organs that protects us from invading pathogens and keeps us healthy and able to resist infections.